Product category:
Assay kits
News Release from: Diagenic
Edited by the Laboratorytalk Editorial
Team on 06 October 2006
Diagenic appoints Erik Christensen as MD
Christensen is currently country manager of the diagnostics division of Abbott Norway and will start in his new role on 1 January 2007
Current managing director and co-founder Anders Loenneborg will take up the position of scientific director Christensen comes to DiaGenic with a strong background in international diagnostics development, marketing and strategy as well as an understanding of the overall diagnostics pathway through previous research and clinical roles
This article was originally published on Laboratorytalk on 24 May 2006 at 8.00am (UK)
Related stories
Parkinson's diagnosis 'breakthrough'
Pilot study shows peripheral blood-based gene expression assay can be employed to discriminate patients with Parkinson's and Alzheimer's disease
Prototypes of early blood test for Alzheimer's
DiaGenic has presented prototypes for its early diagnostic test for Alzheimer's disease at the 8th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2007) at Salzburg, Austria
This combination of experience perfectly matches DiaGenic's needs - the company recently presented breakthrough data on its gene expression signature test for Alzheimer's disease (AD) and is on track to have validated assay designs for both AD and breast cancer ready for large scale clinical trials by the end of the year.
Christensen commented: "I have followed DiaGenic's progress with great interest and now see the opportunity to help develop DiaGenic into an important and significant player internationally in the molecular diagnostics field.
"My experience runs from research, through clinical to commercialisation and it is with this broad knowledge base I will develop the company further".
DiaGenic chairman Hakon Saeteroy also welcomed the appointment: "DiaGenic is now moving into an exciting phase of the company's development with our first two assays approaching clinical trials.
"Erik Christensen has the experience and knowledge needed to ensure we exploit this potential successfully, and we have also been impressed with the way his vision for the DiaGenic matches ours - namely to become a leading player in the new molecular diagnostics market.".
• Diagenic: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
